Telix Pharmaceuticals Ltd ADR TLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $10.72
- Day Range
- $10.45–10.64
- 52-Week Range
- $6.28–13.11
- Bid/Ask
- $10.55 / $10.62
- Shares Outstanding
- 339.78M
- Market Cap
- $3.58B
- Volume/Avg
- 299,612 / 247,716
Key Statistics
- Price/Earnings (Normalized)
- 94.25
- Price/Sales
- 3.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,184
- Website
- https://www.telixpharma.com
Competitors
Valuation
|
Metric
|
TLX
|
VRTX
|
NVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 94.25 | 26.63 | 13.57 |
Price/Book Value | 9.93 | 6.34 | 6.45 |
Price/Sales | 3.94 | 10.32 | 4.80 |
Price/Cash Flow | — | 26.17 | 14.16 |
Price/Earnings
TLX
VRTX
NVS
Financial Strength
|
Metric
|
TLX
|
VRTX
|
NVS
|
|---|---|---|---|
Quick Ratio | 1.74 | 2.54 | 0.55 |
Current Ratio | 2.01 | 3.19 | 0.86 |
Interest Coverage | 1.56 | — | 11.90 |
Quick Ratio
TLX
VRTX
NVS
Profitability
|
Metric
|
TLX
|
VRTX
|
NVS
|
|---|---|---|---|
Return on Assets (Normalized) | 2.08% | 18.99% | 14.74% |
Return on Equity (Normalized) | 6.42% | 26.29% | 39.06% |
Return on Invested Capital (Normalized) | 5.73% | 21.93% | 21.25% |
Return on Assets
TLX
VRTX
NVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|T^bmTz | LOCK|B!CX | $128B | |||
| Moderna Inc
MRNA
| LOCK|vm$h!gW | LOCK|<x | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|JNZJ<% | LOCK|lF$> | $76B | |||
| argenx SE ADR
ARGX
| LOCK|#zr?<pQ | LOCK|KMT | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<<l#BQ | LOCK|D^ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PhWjnWj | LOCK|?#?>l | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?^p%%##! | LOCK|qF>PR | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|zr$R#p | LOCK|Bg | $24B | |||
| Incyte Corp
INCY
| LOCK|S$vkTg< | LOCK|$$ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<F@&^& | LOCK|!MZ | $15B |
United States